Arkolith/Insider Trading/ARWR/Form 4

Anzalone Christopher Richard

Chief Executive Officer, DirectorARROWHEAD PHARMACEUTICALS, INC. (ARWR) · full profile →Form 4 · filed Apr 11, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 11, 2025Sell(S)51K$11.49$584K3.9M
Apr 10, 2025Sell(S)50K$10.87$544K4.0M
Apr 9, 2025Sell(S)2K$11.76$19K4.0M
Apr 9, 2025Sell(S)3K$10.75$37K4.0M
Apr 9, 2025Sell(S)35K$9.93$351K4.0M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-017592) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML